Copyright
©The Author(s) 2022.
World J Clin Cases. Mar 26, 2022; 10(9): 2733-2742
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2733
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2733
First surgery (n = 386), % | Second surgery (n = 155), % | Third surgery (n = 41), % | P value | |
Sex | 0.405 | |||
Man | 290 (76.69) | 124 (80.00) | 33 (80.49) | |
Female | 96 (23.31) | 31 (20.00) | 8 (19.51) | |
Age (year) | 0.037 | |||
A1 (≤ 16) | 5 (1.30) | 2 (1.29) | 0 (00.00) | |
A2 (17-40) | 264 (68.39) | 92 (59.35) | 20 (48.78) | |
A3 (> 40) | 117 (30.31) | 61 (39.35) | 21 (51.22) | |
Appendectomy | 0.152 | |||
Yes | 76 (19.69) | 37 (23.87) | 13 (31.70) | |
No | 310 (80.31) | 118 (76.13) | 28 (68.29) | |
Smoking history | 0.576 | |||
Never smoker | 320 (82.90) | 128 (82.58) | 37 (90.24) | |
Past smoker | 49 (12.69) | 23 (14.84) | 3 (7.32) | |
Active smoker | 17 (4.40) | 4 (2.58) | 1 (2.44) | |
Preoperative treatment | ||||
Immunomodulator | 97 (25.13) | 48 (30.97) | 12 (29.27) | 0.362 |
Enteral Nutrition | 178 (46.11) | 80 (51.61) | 16 (39.02) | 0.288 |
5-aminosalicylates | 32 (8.29) | 23 (14.84) | 4 (9.76) | 0.074 |
Corticosteroids | 49 (12.69) | 30 (19.35) | 7 (17.07) | 0.130 |
Infliximab | 8 (2.07) | 5 (3.23) | 1 (2.44) | 0.743 |
Perianal disease | 0.265 | |||
Yes | 73 (16.77) | 39 (25.16) | 9 (21.95) | |
No | 313 (83.22) | 116 (74.84) | 32 (78.05) | |
Indication for surgery | 0.004 | |||
Free perforation | 65 (16.83) | 9 (5.81) | 2 (4.87) | |
Fistula or abscess | 107 (27.72) | 78 (50.32) | 25 (60.97) | |
Obstruction | 162 (41.96) | 57 (36.77) | 10 (24.39) | |
Medical intractability | 41 (10.62) | 5 (3.23) | 1 (2.44) | |
Hemorrhage | 11 (2.85) | 6 (3.87) | 3 (7.32) | |
Location | 0.028 | |||
L1 (ileal) | 145 (37.56) | 56 (36.13) | 10 (24.39) | |
L2 (colonic) | 47 (12.18) | 7 (4.52) | 5 (12.20) | |
L3 (ileocolonic) | 194 (50.26) | 92 (59.35) | 26 (63.41) | |
IASCs | 0.569 | |||
Yes | 27 (6.99) | 15 (9.68) | 3 (7.32) | |
No | 359 (93.01) | 140 (90.32) | 38 (92.68) |
Covariates | Univariate | Multivariate | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age at diagnosis | 1.000 | 0.987-1.014 | 0.966 | |||
Preoperative duration | 1.003 | 1.000-1.006 | 0.021 | 1.002 | 0.999-1.005 | 0.112 |
Age | 1.005 | 0.992-1.018 | 0.496 | 1.004 | 0.991-1.018 | 0.533 |
Sex | 0.934 | 0.628-1.387 | 0.734 | |||
Appendectomy | 1.288 | 0.874-1.898 | 0.200 | |||
Smoking history | 1.026 | 0.676-1.558 | 0.903 | 1.048 | 0.670-1.639 | 0.838 |
Preoperative treatment | 0.915 | 0.630-1.330 | 0.642 | |||
Perianal disease | 0.925 | 0.606-1.413 | 0.719 | 0.951 | 0.619-1.461 | 0.819 |
Location | 1.027 | 0.864-1.222 | 0.761 | 1.040 | 0.871-1.241 | 0.665 |
Perforating indication | 1.456 | 1.051-2.016 | 0.024 | 1.425 | 1.015-2.000 | 0.041 |
Resection range | 0.949 | 0.799-1.128 | 0.553 | |||
IASCs | 0.666 | 0.381-1.164 | 0.154 |
Covariates | Univariate | Multivariate | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Preoperative duration | 0.998 | 0.990-1.007 | 0.666 | 1.001 | 0.991-1.011 | 0.872 |
Interval from first to second | 1.001 | 0.992-1.010 | 0.831 | |||
Age at diagnosis | 1.012 | 0.984-1.041 | 0.406 | |||
Sex | 0.804 | 0.368-1.755 | 0.583 | |||
Appendectomy | 0.822 | 0.419-1.610 | 0.567 | |||
Smoking history | 0.918 | 0.323-2.606 | 0.872 | 1.228 | 0.371-4.065 | 0.737 |
Preoperative treatment | 1.349 | 0.667-2.752 | 0.405 | |||
Perianal disease | 1.554 | 0.673-3.592 | 0.302 | 1.448 | 0.593-3.532 | 0.416 |
Age | 1.008 | 0.980-1.036 | 0.590 | 1.009 | 0.977-1.042 | 0.579 |
Location | 1.130 | 0.798-1.600 | 0.491 | 1.182 | 0.802-1.742 | 0.397 |
Perforating indication | 2.036 | 1.043-3.968 | 0.037 | 1.919 | 0.959-3.846 | 0.065 |
Resection range | 0.955 | 0.682-1.337 | 0.788 | |||
IASCs | 0.862 | 0.378-1.966 | 0.725 |
- Citation: Shen WS, Huang XH, Liu RQ, Li CY, Li Y, Zhu WM. Perforating and nonperforating indications in repeated surgeries for Crohn’s disease. World J Clin Cases 2022; 10(9): 2733-2742
- URL: https://www.wjgnet.com/2307-8960/full/v10/i9/2733.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i9.2733